CXCL9, CXCL10, and CCL19 synergistically recruit T lymphocytes to skin in lichen planus. | CXCL9, CXCL10, and CCL19 synergistically recruit T lymphocytes to skin in lichen planus. Kersh AE, Sati S, Huang J, Murphy C, Ahart O, Leung TH., Free PMC Article | 10/30/2024 |
Deciphering the mediating role of CXCL10 in hypothyroidism-induced idiopathic pulmonary fibrosis in European ancestry: a Mendelian randomization study. | Deciphering the mediating role of CXCL10 in hypothyroidism-induced idiopathic pulmonary fibrosis in European ancestry: a Mendelian randomization study. Xing X, Zhao C, Cai S, Wang J, Zhang J, Sun F, Huang M, Zhang L., Free PMC Article | 09/24/2024 |
Dysregulated tryptophan metabolism and AhR pathway contributed to CXCL10 upregulation in stable non-segmental vitiligo. | Dysregulated tryptophan metabolism and AhR pathway contributed to CXCL10 upregulation in stable non-segmental vitiligo. Chen Z, Li Y, Tan X, Nie S, Chen B, Mei X, Wu Z. | 08/16/2024 |
Mechanistic insights into SARS-CoV-2 spike protein induction of the chemokine CXCL10. | Mechanistic insights into SARS-CoV-2 spike protein induction of the chemokine CXCL10. Ghazanfari D, Courreges MC, Belinski LE, Hogrell MJ, Lloyd J, C Bergmeier S, McCall KD, Goetz DJ., Free PMC Article | 08/8/2024 |
Expression of ISG60 is induced by TLR3 signaling in BEAS-2B bronchial epithelial cells: Possible involvement in CXCL10 expression. | Expression of ISG60 is induced by TLR3 signaling in BEAS‑2B bronchial epithelial cells: Possible involvement in CXCL10 expression. Tanaka Y, Imaizumi T, Kobori Y, Tachizaki M, Shiratori T, Dobashi M, Sato M, Kawaguchi S, Seya K, Tasaka S. | 07/29/2024 |
Increased CXCL10 (IP-10) is associated with advanced myeloproliferative neoplasms and its loss dampens erythrocytosis in mouse models. | Increased CXCL10 (IP-10) is associated with advanced myeloproliferative neoplasms and its loss dampens erythrocytosis in mouse models. Belmonte M, Cabrera-Cosme L, Øbro NF, Li J, Grinfeld J, Milek J, Bennett E, Irvine M, Shepherd MS, Cull AH, Boyd G, Riedel LM, Chi Che JL, Oedekoven CA, Baxter EJ, Green AR, Barlow JL, Kent DG. | 07/15/2024 |
Augmentation of tumor expression of HLA-DR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responses. | Augmentation of tumor expression of HLA-DR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responses. Larkin RM, Lopez DC, Robbins YL, Lassoued W, Canubas K, Warner A, Karim B, Vulikh K, Hodge JW, Floudas CS, Gulley JL, Gallia GL, Allen CT, London NR Jr., Free PMC Article | 06/7/2024 |
Coinfection with respiratory syncytial virus and rhinovirus increases IFN-lambda1 and CXCL10 expression in human primary bronchial epithelial cells. | Coinfection with respiratory syncytial virus and rhinovirus increases IFN-λ1 and CXCL10 expression in human primary bronchial epithelial cells. Sankuntaw N, Punyadee N, Chantratita W, Lulitanond V. | 05/7/2024 |
Induction of SK-MEL-28 Invasion by Brain Cortical Cell-Conditioned Medium Through CXCL10 Signaling. | Induction of SK-MEL-28 Invasion by Brain Cortical Cell-Conditioned Medium Through CXCL10 Signaling. Sampaio MCPD, Santos RVC, Albuquerque APB, Soares AKA, Cordeiro MF, da Rosa MM, Pereira MC, da Rocha Pitta MG, Rêgo MJBM. | 05/6/2024 |
The IFN-gamma-CXCL9/CXCL10-CXCR3 axis in vitiligo: Pathological mechanism and treatment. | The IFN-γ-CXCL9/CXCL10-CXCR3 axis in vitiligo: Pathological mechanism and treatment. Liu H, Wang Y, Le Q, Tong J, Wang H. | 04/17/2024 |
Circulating TNF-RII, IP-10 and HGF are associated with severity of COVID-19 in oncologic patients. | Circulating TNF-RII, IP-10 and HGF are associated with severity of COVID-19 in oncologic patients. Carrillo-García J, Lacerenza S, Hindi N, Moura DS, Marquina G, Parra Corral D, Olalla J, María Cano Cano J, Hoyos S, Renshaw M, Mondaza-Hernández JL, Di Lernia D, Casado A, Manzano A, Gutierrez A, Martin-Broto J. | 03/29/2024 |
The CXCL10-CXCR3 axis plays an important role in Kawasaki disease. | The CXCL10-CXCR3 axis plays an important role in Kawasaki disease. Hosaka S, Imagawa K, Yano Y, Lin L, Shiono J, Takahashi-Igari M, Hara H, Hayashi D, Imai H, Morita A, Fukushima H, Takada H., Free PMC Article | 03/13/2024 |
Association between Circulating Levels of CXCL9 and CXCL10 and Physical Frailty in Older Adults. | Association between Circulating Levels of CXCL9 and CXCL10 and Physical Frailty in Older Adults. Li J, Hosoyama T, Shigemizu D, Yasuoka M, Kinoshita K, Maeda K, Takemura M, Matsui Y, Arai H, Satake S. | 03/5/2024 |
Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis. | Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis. Prapiadou S, Živković L, Thorand B, George MJ, van der Laan SW, Malik R, Herder C, Koenig W, Ueland T, Kleveland O, Aukrust P, Gullestad L, Bernhagen J, Pasterkamp G, Peters A, Hingorani AD, Rosand J, Dichgans M, Anderson CD, Georgakis MK., | 03/4/2024 |
Plasma interferon-gamma-inducible-protein 10 level as a predictive factor of spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B patients. | Plasma interferon-gamma-inducible-protein 10 level as a predictive factor of spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B patients. Kan K, Wong DK, Hui RW, Seto WK, Yuen MF, Mak LY. | 02/7/2024 |
Natural carboxyterminal truncation of human CXCL10 attenuates glycosaminoglycan binding, CXCR3A signaling and lymphocyte chemotaxis, while retaining angiostatic activity. | Natural carboxyterminal truncation of human CXCL10 attenuates glycosaminoglycan binding, CXCR3A signaling and lymphocyte chemotaxis, while retaining angiostatic activity. Dillemans L, Yu K, De Zutter A, Noppen S, Gouwy M, Berghmans N, Verhallen L, De Bondt M, Vanbrabant L, Brusselmans S, Martens E, Schols D, Verschueren P, Rosenkilde MM, Marques PE, Struyf S, Proost P., Free PMC Article | 02/7/2024 |
CXCL10 as a biomarker of interstitial lung disease in patients with rheumatoid arthritis. | CXCL10 as a biomarker of interstitial lung disease in patients with rheumatoid arthritis. Makarem YS, Ahmed EA, Makboul M, Farghaly S, Mostafa N, El Zohne RA, Goma SH. | 01/30/2024 |
Obesity-related Plasma CXCL10 Drives CX3CR1-dependent Monocytic Secretion of Macrophage Migration Inhibitory Factor. | Obesity-related Plasma CXCL10 Drives CX3CR1-dependent Monocytic Secretion of Macrophage Migration Inhibitory Factor. Meyhöfer S, Steffen A, Plötze-Martin K, Marquardt JU, Meyhöfer SM, Bruchhage KL, Pries R., Free PMC Article | 01/8/2024 |
CXCL10 Expression in Human Colorectal Cancer Tissue and its Correlation With Serum Levels of CXCL10. | CXCL10 Expression in Human Colorectal Cancer Tissue and its Correlation With Serum Levels of CXCL10. Li L, Kanemitsu K, Ohnishi K, Yamada R, Yano H, Fujiwara Y, Miyamoto Y, Mikami Y, Hibi T, Baba H, Komohara Y., Free PMC Article | 01/5/2024 |
High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies. | High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies. Al-Adwi Y, Atzeni IM, Doornbos-van der Meer B, van der Leij MJ, Varkevisser RDM, Kroesen BJ, Stel A, Timens W, Gan CT, van Goor H, Westra J, Mulder DJ., Free PMC Article | 12/21/2023 |
Prediction of spontaneous preterm birth using CCL2 and CXCL10 in maternal serum of symptomatic high-risk pregnant women: a prospective cohort study. | Prediction of spontaneous preterm birth using CCL2 and CXCL10 in maternal serum of symptomatic high-risk pregnant women: a prospective cohort study. Hoffmann JA, Gründler K, Richter DU, Stubert J., Free PMC Article | 11/27/2023 |
Profile and clinical significance of interferon gamma-inducible protein-10 (IP-10) and its receptor in patients with hepatocellular carcinoma. | Profile and clinical significance of interferon gamma-inducible protein-10 (IP-10) and its receptor in patients with hepatocellular carcinoma. Li Y, Wang C, Yin X, Jiang L, Li X, Yang J. | 11/1/2023 |
Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma. | Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma. Miura Y, Motoshima T, Anami T, Yano H, Mito R, Pan C, Urakami S, Kinowaki K, Tsukamoto H, Kurahashi R, Murakami Y, Yatsuda J, Fujiwara Y, Kamba T, Komohara Y. | 10/20/2023 |
Relationship between Plasma IP-10/CXCL10 Levels and the Initial Therapeutic Response in Patients Treated with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma. | Relationship between Plasma IP-10/CXCL10 Levels and the Initial Therapeutic Response in Patients Treated with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma. Takada H, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Kobayashi S, Yoshida T, Takano S, Maekawa S, Enomoto N. | 10/16/2023 |
Investigating Association Level of CXCL12 with its SDF-1alpha 3'A Genetic Variant and CXCL10 with its 1443 Promoter Polymorphism in Type-1 Diabetes. | Investigating Association Level of CXCL12 with its SDF-1α 3'A Genetic Variant and CXCL10 with its 1443 Promoter Polymorphism in Type-1 Diabetes. Derakhshan S, Hassanshahi G, Karimabad MN, Torabizadeh SA. | 09/1/2023 |